Cmed is a UK based full service, oncology focused contract research organisation with operations in Romania, France and the USA. It specialises in complex disease areas, particularly oncology, immuno-oncology, cell therapy and other specialty therapeutics areas where clinical trials are increasingly complex and demanding. Cmed provides expertise and a next generation clinical data platform to a blue chip client base and has an established a track record of delivering early phase clinical projects quickly and cost effectively. Cmed has also developed encapsia, a next generation software suite for the remote gathering and management of clinical trial data.

In 2021 Cmed Group was acquired by the French Aixial Group, a leader in contact research organisation (CRO) services and part of Alten, the global engineering and technology consultancy business. Aixial has over 1,000 employees across the United States and Europe and the acquisition will enable Cmed to build out its capabilities and expand its global presence.

‍